semaglutide shortage news november 2025 Hims: Why The May End Imminently Minnesota doctor says FDA weight-loss

, Semaglutide 68 14%

Click the link and transform today:

For U.S

These results highlight significant heterogeneity in weight trajectories following sustained exposure to a GLP-1RA therapy and identifies factors associated with increased weight loss, likely reflecting a combination of biological, behavioral, and social factors

Weve all heard that stopping taking a GLP-1 medication for weight losssuch as semaglutide (marketed as Wegovy) and tirzepatide (sold as Zepbound)often leads to rapid weight gain, with people returning to baseline in as little as 18 months

As such, there is growing interest in repurposing medications with novel mechanisms of action